Dr. Scott Gottlieb alerted Thursday about the capacity for long-lasting brain loss related to Covid, mentioning a brand-new research study from the United Kingdom.
“In short, the study suggests that there could be some long-term loss of brain tissue from Covid, and that would have some long-term consequences,” the previous FDA chief and CNBC factor stated.
“You could compensate for that over time, so the symptoms of that may go away, but you’re never going to regain the tissue if, in fact, it’s being destroyed as a result of the virus,” stated Gottlieb, who serves on the board of Covid vaccine-maker Pfizer.
The U.K. research study analyzed brain imaging prior to and after a coronavirus infection and looked particularly at the possible result on the nerve system.
Gottlieb discussed to CNBC’s “The News with Shepard Smith” that the damage of brain tissue might describe why Covid clients lost their sense of odor.
“The diminishment in the amount of cortical tissue happened to be in regions of the brain that are close to the places that are responsible for smell,” he stated. “What it suggests is that, the smell, the loss of smell, is just an effect of a more primary process that’s underway, and that process is actually shrinking of cortical tissue.”
Disclosure: Scott Gottlieb is a CNBC factor and belongs to the boards of Pfizer, hereditary screening start-up Tempus, health-care tech business Aetion Inc. and biotech business Illumina.
